84 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
Structure-Activity Relationships of Small Molecule Autotaxin Inhibitors with a Discrete Binding Mode.
University of Strathclyde
Highly Potent Non-Carboxylic Acid Autotaxin Inhibitors Reduce Melanoma Metastasis and Chemotherapeutic Resistance of Breast Cancer Stem Cells.
University of Tennessee Health Science Center
Discovery of potent inhibitors of the lysophospholipase autotaxin.
Babraham Research Campus
Development of Autotaxin Inhibitors: An Overview of the Patent and Primary Literature.
University of Strathclyde
Vinyl sulfone analogs of lysophosphatidylcholine irreversibly inhibit autotaxin and prevent angiogenesis in melanoma.
The University of Georgia
Imidazopyridine- and purine-thioacetamide derivatives: potent inhibitors of nucleotide pyrophosphatase/phosphodiesterase 1 (NPP1).
Ku Leuven
Autotaxin inhibition: development and application of computational tools to identify site-selective lead compounds.
The University of Memphis
The chemical synthesis of metabolically stabilized 2-OMe-LPA analogues and preliminary studies of their inhibitory activity toward autotaxin.
Technical University of Lodz
Pharmacophore development and application toward the identification of novel, small-molecule autotaxin inhibitors.
The University of Memphis
Aromatic phosphonates inhibit the lysophospholipase D activity of autotaxin.
The University of Utah
Structure-based design of novel boronic acid-based inhibitors of autotaxin.
The Netherlands Cancer Institute
Synthesis and structure-activity relationships of tyrosine-based inhibitors of autotaxin (ATX).
University of Virginia
Synthesis and pharmacological evaluation of the stereoisomers of 3-carba cyclic-phosphatidic acid.
University of Tennessee Health Science Center
Drugs for the treatment of glaucoma: Targets, structure-activity relationships and clinical research.
Chengdu Sport University
Targeting Metalloenzymes by Boron-Containing Metal-Binding Pharmacophores.
Sichuan University
Structure-Based Design of a Novel Class of Autotaxin Inhibitors Based on Endogenous Allosteric Modulators.
University of Strathclyde
Design, synthesis and promising anti-tumor efficacy of novel imidazo[1,2-a]pyridine derivatives as potent autotaxin allosteric inhibitors.
Shenyang Pharmaceutical University
Identification of Darmstoff analogs as selective agonists and antagonists of lysophosphatidic acid receptors.
University of Tennessee Health Science Center
Synthesis and pharmacological evaluation of second-generation phosphatidic acid derivatives as lysophosphatidic acid receptor ligands.
University of Tennessee Health Science Center
Structural and PK-guided identification of indole-based non-acidic autotaxin (ATX) inhibitors exhibiting high in vivo anti-fibrosis efficacy in rodent model.
Shenyang Pharmaceutical University
Recent applications of vinyl sulfone motif in drug design and discovery.
Mazandaran University of Medical Sciences
Dual target inhibitors based on EGFR: Promising anticancer agents for the treatment of cancers (2017-).
Zhuhai Campus of Zunyi Medical University
Novel Pyridazines as Autotaxin Inhibitors for Treating Inflammatory Airway or Fibrotic Diseases.
Smith, Gambrell & Russell
Design, synthesis and anti-fibrosis evaluation of imidazo[1,2-a]pyridine derivatives as potent ATX inhibitors.
Shenyang Pharmaceutical University
Structure guided design of potent indole-based ATX inhibitors bearing hydrazone moiety with tumor suppression effects.
Shenyang Pharmaceutical University
Therapeutic Potential of Autotaxin Inhibitors in Treatment of Interstitial Lung Diseases.
Therachem Research Medilab
Structure-based linker exploration: Discovery of 1-ethyl-1H-indole analogs as novel ATX inhibitors.
Shenyang Pharmaceutical University
Novel Pyridazines as Autotaxin Inhibitors for Treating Inflammatory Airway or Fibrotic Diseases.
Smith, Gambrell & Russell
Optimization and evaluation of novel tetrahydropyrido[4,3-d]pyrimidine derivatives as ATX inhibitors for cardiac and hepatic fibrosis.
Shenyang Pharmaceutical University
Development of autotaxin inhibitors: A series of tetrazole cinnamides.
Novartis Institutes For Biomedical Research
ONO-8430506: A Novel Autotaxin Inhibitor That Enhances the Antitumor Effect of Paclitaxel in a Breast Cancer Model.
Ono Pharmaceutical
Discovery of Novel Indole-Based Allosteric Highly Potent ATX Inhibitors with Great
Shenyang Pharmaceutical University
Novel Autotaxin Inhibitor for the Treatment of Idiopathic Pulmonary Fibrosis: A Clinical Candidate Discovered Using DNA-Encoded Chemistry.
X-Chem
Novel Autotaxin Inhibitors for the Treatment of Osteoarthritis Pain: Lead Optimization via Structure-Based Drug Design.
Lilly Research Laboratories
Discovery and synthetic optimization of a novel scaffold for hydrophobic tunnel-targeted autotaxin inhibition.
University of Memphis
Synthesis, biological evaluation, and molecular docking study of sulfonate derivatives as nucleotide pyrophosphatase/phosphodiesterase (NPP) inhibitors.
University of Sharjah
Rational Design of Autotaxin Inhibitors by Structural Evolution of Endogenous Modulators.
The Netherlands Institute
Discovery and optimization of ATX inhibitors via modeling, synthesis and biological evaluation.
Chungnam National University
Discovery of BI-2545: A Novel Autotaxin Inhibitor That Significantly Reduces LPA Levels in Vivo.
Boehringer Ingelheim Pharma
Development of autotaxin inhibitors: A series of zinc binding triazoles.
Novartis Institutes For Biomedical Research
Design, synthesis, docking and biological evaluation of 4-phenyl-thiazole derivatives as autotaxin (ATX) inhibitors.
Chungnam National University
Repurposing Suzuki Coupling Reagents as a Directed Fragment Library Targeting Serine Hydrolases and Related Enzymes.
Takeda California
Discovery of 2-[[2-Ethyl-6-[4-[2-(3-hydroxyazetidin-1-yl)-2-oxoethyl]piperazin-1-yl]-8-methylimidazo[1,2-a]pyridin-3-yl]methylamino]-4-(4-fluorophenyl)thiazole-5-carbonitrile (GLPG1690), a First-in-Class Autotaxin Inhibitor Undergoing Clinical Evaluation for the Treatment of Idiopathic Pulmonary Fib
Galapagos
Hydroxamic Acids Constitute a Novel Class of Autotaxin Inhibitors that Exhibit in Vivo Efficacy in a Pulmonary Fibrosis Model.
National and Kapodistrian University of Athens
Discovery, Structure-Activity Relationship, and Binding Mode of an Imidazo[1,2-a]pyridine Series of Autotaxin Inhibitors.
Galapagos